Nephrodite’s device designed to ‘free patients from the cycle of center-based dialysis’ becomes the first to receive the designation.
Medical device startup Nephrodite has received Breakthrough Device Designation from the US FDA for its implantable synthetic kidney system. The Atlanta-based company claims it is the first implantable continuous renal replacement device to receive the designation, which should accelerate its path toward first-in-human clinical studies.
The Breakthrough Device program recognizes technologies that have the potential to offer more effective treatment for life-threatening or irreversibly debilitating conditions. In this case, the FDA recognized the potential of Nephrodite’s device, dubbed “Holly”, to change the treatment landscape for end-stage kidney disease. For decades, patients have had only two real options: dialysis or transplant. Dialysis, first developed in the 1940s, sustains life but often requires hours of treatment several times a week, repeated needle access, and constant scheduling around clinic visits. Transplantation, while life-changing for some, is limited by organ availability and the lifelong burden of immunosuppression.
“Dialysis sustains life, but at tremendous cost to a patient’s freedom and physiology,” said Nephrodite’s head of science and technology Dr Hiep T Nguyen. “Holly represents a complete rethinking of kidney replacement, with a continuously functioning implant capable of matching the body’s natural rhythm. It’s both a scientific milestone and a human one.”
Nephrodite is aiming to change the paradigm with a fully implantable system designed to replace kidney function continuously inside the body. Holly is engineered to filter waste, manage fluid balance, and regulate electrolytes around the clock. The internal implant is designed to work in conjunction with a small, portable external unit used at home, typically overnight, allowing patients to move freely through the day without being tethered.
“Holly was designed from the ground up to free patients from the cycle of center-based dialysis,” said Nephrodite CEO Dr Nikhil L Shah. Breakthrough status enables close collaboration with regulators and accelerates our path toward first-in-human studies.”
Nephrodite’s Breakthrough Device application was supported by data from a successful multi-day large animal study in which the system demonstrated sustained kidney function replacement along with favorable safety and performance outcomes. The company says it is now preparing for Good Laboratory Practice studies and subsequent regulatory submissions required to initiate clinical trials in humans, with the designation allowing it to work more closely with the FDA and benefit from expedited review pathways as development progresses.
Until now, probably the most well-known bioartificial kidney was being developed by The Kidney Project at UCSF, but Nephrodite has now emerged as a potential frontrunner in the race to develop an implantable synthetic solution.
